LONDON, ONTARIO--(Marketwire - Oct. 19, 2011) - Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that 71,449 stock options were approved for grant under the Company's Stock Option Plan on October 18, 2011, to its nine employees as part of their compensation for the fiscal 2012 year. The options vested immediately, have a life of five years and are exercisable at a price of $0.25 per share. The exercise price represents the closing price of the Company's common shares on October 17, 2011, the last trade reported on the TSX Venture Exchange prior to the approval date.

About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, please visit our website [ www.criticaloutcome.com ].

Publication Contributing Sources

• Market Wire